Hepatotoxicity: pathogenesis and therapeutic intervention.
D000082:Acetaminophen / Q000009:adverse effects; D045930:Anabolic Agents / Q000009:adverse effects; D000728:Androgens / Q000009:adverse effects; D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D003543:Cysteamine / Q000627:therapeutic use; D003545:Cysteine / Q000627:therapeutic use; D004917:Erythromycin / Q000009:adverse effects; D004967:Estrogens / Q000009:adverse effects; D006221:Halothane / Q000009:adverse effects; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D008099:Liver / Q000187:drug effects*; D009582:Nitrofurantoin / Q000009:adverse effects; D012293:Rifampin / Q000009:adverse effects
D045930:Anabolic Agents; D000728:Androgens; D004967:Estrogens; D000082:Acetaminophen; D003543:Cysteamine; D004917:Erythromycin; D009582:Nitrofurantoin; D003545:Cysteine; D006221:Halothane; D007538:Isoniazid; D012293:Rifampin